ImmunoGen Cash Flow - Quarterly (NASDAQ:IMGN)

Add to My Stocks
$8.82 $0.22 (2.43%) IMGN stock closing price Sep 19, 2018 (Closing)

The financial analysis of IMGN requires an investor to check the cash flows for ImmunoGen. The profit-loss statement shows ImmunoGen profits, the balance sheet shows ImmunoGen debt, and the cash flow statement reflects the liquidity and solvency of a firm. This statement reflects the company's ability to generate cash flows. ImmunoGen stock analysis shows negative net income cash flow of $-80.24M till 2018 Q2. This statement is important because profits alone cannot pay employees, or bills. Cash is required. ImmunoGen saw a outflow of $-2.13M from investing activities till 2018 Q2.

View and download details of ImmunoGen cash flows for latest & last 40 quarters
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow5.06M2.52M5.96M4.3M2.93M1.5M-1.52M5.32M3.82M
Net Increase (Decrease) in Assets Liabilities-9.11M-13.55M77.58M94.83M15.34M-15.95M--9M-2.2M-10.05M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net-0.99M-0.31M20.11M20.8M-0.94M-1.16M-4.36M17.21M13.55M
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-2.13M-1.02M-1.11M-0.84M-0.77M-0.43M--1.18M-10.37M-8.6M
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments----------
Other Cash Inflow (Outflow) from Investment Activities----------
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares165.36M2.25M102.31M-----101.76M4.97M
Issuance (Repayment) of Debt Securities----------
Increase (Decrease) in Bank & Other Borrowings---1.69M-1.68M------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities----------
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash----------
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year267.11M159.96M159.96M278.1M142.26M194.96M160.93M191.2M109.15M69.63M
Cash & Equivalents at Year End345.06M218.38M267.1M194.85M150.33M126.56M-196M245.02M182.91M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

ImmunoGen stock price history provides insight into historical stock price fluctuations, and ImmunoGen stock comparison chart enables peer comparison. Some of the key terms used in the statement of cash flows are:

  • ImmunoGen had a Net Change in Cash and Cash Equivalents of $77.95M in the latest quarter 2018 Q2. If a firm is able to grow its cash, it is considered to be a positive signal and could lead to a jump in the ImmunoGen stock price, albeit too much cash on hand can imply the company has no or limited avenues for growth in which to invest this cash.
  • Cash Flow from operating activities: This is the cash that the company receives from ongoing operations. ImmunoGen lost $-85.28M cash from operations. It is important to check this to see where the company is getting its money from.
  • Cash from investing stood at a negative value of $-2.13M for IMGN stock. A company with surplus cash usually thinks of re-investing it in the form of buying fixed assests, or purchasing plant/ machinery which will help grow the business further. By looking at cash flow from investment activities one can check where the company is putting its cash.
  • Cash flow from financing activities shows the flow of cash between ImmunoGen and its owners and creditors and was $165.36M till 2018 Q2. Financing activities allow a company to raise capital, and repay bondholders.

Key Financial Ratios For ImmunoGen Cash Flow

Quarterly Cash Flow Statements For ImmunoGen, Inc. Peers

Amgen cash flow, Seattle Genetics cash flow, Takeda Pharma cash flow, TherapeuticsMD cash flow